Summary

EXAS is on a huge rally due to Pfizer deal.

The deal is a result of weakness though, not strength.

I still believe EXAS makes it to $100/share in the next few years, but the easy money has been made.

EXAS is at the top of trading range and should not represent more than about 2% of your overall holdings now (and zero is fine).

Exact Sciences (EXAS) recently cut a marketing deal with Pfizer (PFE) for Cologuard. That will greatly improve the market penetration of Exact's highly effective and noninvasive colon cancer test. As a result, short sellers have been covering their positions, driving the stock nearly straight up the past few days.

To read more, a subscription is needed: Click here to subscribe